

Pursuant to article 227 of the Spanish Securities Market Act (*Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios de Inversión*), Inmobiliaria Colonial, SOCIMI, S.A. ("**Colonial**" or the "**Company**") hereby discloses the following

OTHER RELEVANT INFORMATION (OTRA INFORMACIÓN RELEVANTE)

Following the "Other Relevant Information" (*Otra Información Relevante*) announcement published on the 22nd of April 2025, with the registered number 34201, Colonial publishes the documentation to support the presentation to analysts and investors that will be held today, Tuesday, 22nd of April 2025 at 6:30 PM (CET) through a webcast.

The conference call connection details are the following:

France (Paris) +33 172 00 1700

Germany (Munich) +49 891 436 7081

Netherland (Amsterdam) +31 20 795 2680

Spain (Madrid) +34 917 91 85 80

UK (London) +44 20 3428 1388

USA (New York) + 1 917 444 9040

Conference ID: 345 632

The presentation can be followed in real-time via webcast with audioconference through the following link:

Inmobiliaria Colonial - Alpha Investment

In addition, the presentation will be available on the website of the Company.

In Madrid, April 22nd, 2025





DISCLAIMER

By attending this presentation and receiving this document, you are agreeing to be bound by the following limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws and/or may result in civil, administrative or criminal liabilities.

This document is strictly confidential and is being furnished to you solely for your information. It may not be reproduced, or redistributed to any other person, and it may not be published, in whole or in part, for any purpose.

The information contained in this presentation ("Presentation") has been prepared by Inmobiliaria Colonial, SOCIMI S.A. (the "Company") and has not been independently verified and will not be updated. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein and nothing in this Presentation is, or shall be relied upon as, a promise or representation. None of the Company nor any of its employees, officers, directors, advisers, representatives, agents or affiliates shall have any liability whatsoever (in negligence or otherwise, whether direct or indirect, in contract, tort or otherwise) for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation.

This Presentation is for information purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by the Company and the Company's publicly available information. The information and opinions in this presentation are provided as at the date hereof and subject to change without notice. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.

This Presentation does not constitute investment, legal, accounting, regulatory, taxation or other advice and does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and for making your own independent assessment of the Company. You are solely responsible for seeking independent professional advice in relation to the Company. No responsibility or liability is accepted by any person for any of the information or for any action taken by you or any of your officers, employees, agents or associates on the basis of such information.

This Presentation contains financial information regarding the businesses and assets of the Company. Such financial information may not have been audited, reviewed or verified by any independent accounting firm. The inclusion of such financial information in this Presentation or any related presentation should not be regarded as a representation or warranty by the Company, its affiliates, advisors or representatives or any other person as to the accuracy or completeness of such information's portrayal of the financial condition or results of operations by the Company and should not be relied upon when making an investment decision. Certain financial and statistical information in this document has been subject to rounding off adjustments. Accordingly, the sum of certain data may not conform to the expressed total.

Certain statements in this Presentation are forward-looking. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing economic, business or other market conditions, changing political conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this Presentation and based upon past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The market and industry data and forecasts included in this Presentation were obtained from internal surveys, estimates, experts and studies, where appropriate as well as external market research, publicly available information and industry publications. The Company, it affiliates, directors, officers, advisors and employees have not independently verified the accuracy of any such market and industry data and forecasts and make no representations or warranties in relation thereto. Such data and forecasts are included herein for information purposes only. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this Presentation.

NEITHER THIS DOCUMENT NOR ANY OF THE INFORMATION CONTAINED HEREIN CONSTITUTES AN OFFER OF PURCHASE, SALE OR EXCHANGE, NOR A REQUEST FOR AN OFFER OF PURCHASE, SALE OR EXCHANGE OF SECURITIES, OR ANY ADVICE OR RECOMMENDATION WITH RESPECT TO SUCH SECURITIES.



Executive Summary

Science & Innovation - Superior Growth -

O3 Creation of a European Leader

Growth Profile & Returns

05 Conclusion



Executive Summary

Science & Innovation - Superior Growth -

Creation of a European Leader

Growth Profile & Returns

Conclusion



Colonial & Stoneshield to set up the Leading Platform in Science and Innovation

Strategic Infraestucture for European Sovereignty in Science & Innovation

Breaking into the Science & Innovation ("S&I") Real Estate

- Colonial invests €200m1 in Deeplabs, the #1 Science & Innovation platform in Spain
- High value add asset class with attractive yield (7-8% stabilized yield on cost)
- Undersupplied segment creating strong ecosystems that attract top tier long term clients

Global megatrends accelerating need for S&I space

- Demographics ageing population driving growing R&D and innovation in Pharma and Wellbeing
- **Technology** AI & technology requiring equipped and more sophisticated space for innovation
- Geopolitics European ambitious plan to boost value-added industries supporting R&D development

Unique partnership between Colonial & Stoneshield

- Colonial to set up with Stoneshield an Asset Management Business Unit
- Shared focus on quality and long-term value creation through urban transformation
- Co-managed third-party capital to accelerate growth

Pan-European Ambition with high double-digit returns

- Market leader with €0.4bn initial assets in consolidated ecosystem & strong operating platform
- Targeting €2.4bn+ platform across Europe, with €0.7bn identified pipeline in the short-term
- Strong growth profile with high yield on costs resulting in +15% geared IRR



¹ Investment volume subject to final closing

Seizing the European Real Estate Opportunity behind Strategic Growth





Joint Venture to create the Leading Pan-European Science & Innovation platform

/deeplabs

- > Strong ecosystems with operating platform
- > Tailored innovative spaces delivered across markets
- > Product transformation with low capex intensity
- > Proven track record in Urban Transformation
- > Leader in Real Estate value creation & capital raising
- > Rapid Pan-European build-up on the back of joint forces

Successful Strategy in Madrid & Barcelona with >30% market share1







Rapid Scale-up of a Pan-European pipeline









Estimated market share in Spanish Life Science Segment

Fast paced industries require innovative Urban Transformation solutions

Urban Transformation - Creating Top Product...









...expanding into high growth industries with increasing demands

Life Sciences & Health

Technology & Quantum

Energy & Environment Aerospace & Defense

Locations enable thriving ecosystems

Experience

Efficiency

Environment

Urban

Campus

Solutions

Complementary Uses

& Amenities

Strong

Science

Ecosystems

Development of the right product with complementary operating services

Colonial is accelerating its Urban Transformation portfolio

Colonial to continue serving its clients' needs through Urban Transformation

Urban Transformation - Value Add Returns with exceptional growth

Strong Returns with superior Growth Profile 85-90% Core with Pricing Power & 10 -15% Value Add

Alpha X - Project Pipeline Total Cost €1bn

> +13% Levered IRR

6-7% Yield on Cost

Urban Mixed Use





Condorcet

Science & Innovation SOCIMI Initial GAV €0.4bn targeting > €2.4bn AuM

> +15% Levered IRR

7-8% Yield on Cost






MADRID SCIENCE AND INNOVATION DISTRICT







Paris





Barcelona



01 Executive Summary

02 Science & innovation - Superior Growth -

Creation of a European Leader

Growth Profile & Returns

Conclusion

R&D industries with increasing demands for Science & Innovation space

Projected Growth in the S&I Sector Supported by strong Fundamentals Current Global Science & Innovation Market The global Science & Innovation market size is estimated at Superior growth on the back of megatrends \$6.3Tn with high growth levels projected Market Size 23-28 CAGR Global Expenditure **Demographics** Technology Geopolitics \$6.3Tn +14% \$11Tn **Expansion of knowledge-based industries** Life Science & Health **Technology & Quantum** - Increasing demand for R&D space to attract talent -✓ Nanotechnology Health tech **Shift towards On-Shoring** Clinical Research √ Robotics - Priority to reallocate major R&D operations in Europe -✓ AI / Machine Learning Genomics Quantum Tech **Pharmaceuticals** Subsectors Bioengineering Semiconductors Increased public budget & private funding - Significant increases of R&D expenditures in Europe -**Energy & Environment** Aerospace & Defense **Environmental sustainability Focus** ✓ Renewable Energy √ Space exploration - Increasing momentum in climate tech efforts, eg: €100bn German budget -Energy Storage Solutions Defense & Cybersecurity Waste Management Aviation Agri Tech Consolidation of successful hubs to attract best Talent √ Future of mobility - Innovation clusters in selected key European cities -Climate Tech Source: Bain & Company, White & Case, CrunchBase, Medical Device

Network, Deloitte, Statista, CBRE analysis.

Strong growth in Science & Innovation on the back of megatrends

- Demographics -

Aging leads to higher investment in Life Science & Wellbeing solutions


EU27 Population with +65 years



In m



European Union Life Expectancy



Source: UN, Eurostat

- Technology -


Enabler of next-gen innovation on quantum, digital & Al

European Union market share of Global semiconductor market





Quantum computing market expected growth



Source: McKinsey & Company


- Geopolitics -

Ambitious plan to fund European value-added Industry and Defense

Strategic on-shoring of Key Industries



European Defense Fund



Source: European Defence Agency

Europe approves unprecedented spending in Research & Development


The future of European Competitiveness (Draghi Report)

EU Compass




Government Budget Allocations for R&D

€bn




Source: Eurostat & EU Commission

EU Research & Development Annual Expenditure



Source: Banque de France




2026

Source: European Defence Agency

2023



To digitalise and decarbonise the economy and increase our defence capacity, the investment share in Europe will have to rise by around 5 percentage points of GDP to levels last seen in the 1960s and 70s.




Source: PitchBook



It proposes ways for Member States to massively invest in defence, procure defence systems and build up the readiness of the European defence industry over the long run. European countries need to target to spend 3-5% of GDP in defence vs current c.1.5%.


Established Science & Innovation ecosystems attract high quality tenants


Science & Innovation is ecosystem based...




- Science & Innovation sector is about micro location and flourishes in locations where an ecosystem can be created
- A distinguished research university/institution that drives the scientific knowledge ensures access to a skilled talent pool
- A dynamic business environment emerges as businesses such as start-ups, university spin-offs and investment firms cluster in the area.
- Combination of talents and businesses attracts funding in the sector

...and benefits from enduring megatrends








Sources: Eurostat, Statista, CW, Moody's, McKinsey, EU Commission

EU 2030 Digital Targets

Key cities with successful clusters attract global demand

Science & Innovation Real Estate is a global megatrend with accelerating growth in Continental Europe and already strong in US & UK



Source: Savills, ULI, CBRE,


Note: Cities in bold refer hotspots for growth sectors. Un-bolded cities are below the threshold for 24/7 gateway cities.

Europe is the emerging Science & Innovation region with accelerated growth

Increasing S&I demand meets undersupplied European market

- Undersupply of stock for flexible, multi-tenant lab space
 - > The laboratory investment market is still relatively nascent, and existing stock is insufficient to meet strong occupier demand
 - > Lack of sector-specific expertise in real estate to develop high-quality lab spaces
- Governments, pharmaceutical & technological companies to onshore R&D and innovation activities within Europe
- Expanding talent pools across Europe fueling the rise of Science & Innovation ecosystems with strong operators
- Increasing momentum in Barcelona & Madrid as international Science & innovation destination

Key European Cities as destination for Science & Innovation¹









Illustrative examples of operating Science & Innovation spaces

Barcelona - the largest innovation ecosystem in Southern Europe

Business innovation ecosystem

- Third favorite city worldwide for R&D investment and the first in Europe (Global Cities Investment Monitor, 2023)
- 12 universities, including UPC¹ (1st in Europe in Math and Computer Sciences scientific production), and UPF² (7th best young university in Europe).



Barcelona Scientific capacity in figures

2nd jobs creation European Union 5,000 2019 - 23

Life Science powerhouse



Highly cited papers




Talent

Universitat Politècnica de Catalunya

Universitat Pompeu Fabra

Source: CBRE. Catalonia Trade & Investment

Leading Science facilities





Center for Genomic Regulation



Institute for Bioengineering



Institut d'Investigacions Biomèdiques Pi I Sunyer



Institut d'Investigacions Biomèdiques Bellvitge



Institut de Recerca Biomèdica



Barcelona Supercomputing



Alba Synchrotron & Innofab



IRSI Caixa



VHIR & VHIO



Madrid - a growing hub for biomedical and pharmaceutical companies

Business innovation ecosystem

- 80% of the world's largest biomedical and pharmaceutical companies are
- Madrid is home to 15 universities, producing more than 30,000 graduates annually in scientific fields



Madrid Scientific capacity in figures



turnover


5,000 Scientific papers

Research Hub



Talent

Leading Science facilities



National Center for Cardiovascular Research



Energy, Environmental & Technological Research Center



Center for Astrobiology



Center for Biomedical Tech



Molecular Biology Center Severo Ochoa



Biotechnology and Genomics



National Center for Oncological Research



Biotechnology National Center



Madrid Institute for Advanced Studies



Institute of Theoretical Physics



Health Institute Carlos III



Research Institute La Paz

Paris - the European destination for global innovation companies

Business innovation ecosystem

- With +25,000 foreign companies, France is the leading business creator in Europe, and is home to 51 research & innovation centers
- Paris is home to some of the world's most influential Science & **Innovation companies**, with their **headquarters** based in the city



Paris epicenter of Science & Innovation investment & output



36% **Publications** of France Research

Hub

Top 1 Continental Europe €2.7bn raised

Venture Capital

Strong political commitment in Science & Innovation

- In 2021 France launched the **Health Innovation Plan 2030**, a €7.5bn investment in healthcare sector
- Priority sectors: Biotherapy, Digital Health and Infectious & Emerging **Diseases**
- PariSanté Campus cornerstone investment in Paris XV arrondissement as a hub for public - private collaboration



Leading Universities & Research

Universities

Incubators

Hospitals

Science Campus





INSTITUT PASTEUR











SACLAY

CANCER









01 Executive Summary

02 Science & innovation - Superior Growth -

03 Creation of a European Leader

Growth Profile & Returns

Conclusion



Deeplabs is the leading Science & Innovation operator in Spain

Pioneering the fully integrated Science & Innovation Spanish platform

- Leadership in Science & Innovation Property Deeplabs is a leading, vertically integrated, Science & Innovation platform in Spain
- Consolidated ecosystems Operates 22 buildings in Science & Innovation key clusters in Madrid & Barcelona, two of the strongest emerging markets in Europe
- Successful S&I campuses in Madrid & Barcelona with world class tenant base - S&I premises including Wet & Dry Lab Space, Research & Technical workspace
- Successful asset transformation Strong credentials in rental growth through asset repositioning, achieving +46% premium over previous rents1
- Superior sourcing capabilities Extensive network of leading S&I national and international clients & ~€700m identified pipeline²

Rental Premium through Tailored Product

Long term Client Commitment

Created Yield Compression


Strong Value Creation Deeplabs: The dominant S&I hub player in Spain



- Total Surface 60k sqm
- Wet & Dry Lab Space 16.1k sqm
- Buildings 5



- Total Surface 78k sqm
- Wet & Dry Lab Space 19.5k sqm
- Buildings 17



Value creation achieved on selected assets in terms of comparable workspace rent per sqm

Includes acquisition cost and capex of identified pipeline

Market share considering Life sciences market

Deeplabs has created successful ecosystems with high quality tenants

A fully integrated platform for unparalleled growth

Fully integrated platform

> Combining Science & Innovation and Real Estate expertise

Operational know-how

- > Personnel with proven extensive sectoral expertise
- > Previous management positions in Madrid Science Park & Barcelona Science Park

Tailor-made solutions

- > Tenant-focused approach allows the identification of client needs and market trends to deliver customized solutions
- > BioInnova consulting services provides valued-added services to foster relationship with tenants and improving long-term retention

Urban transformation

> Colonial's proficiency at urban transformation paired with deep understanding of the tenant requirements, is poised to create a prime state-of-the-art customercentric solution

An attraction pole of global Science & Innovation







Successful ecosystems enable rental premiums, longer leases & asset value creation


Our Ecosystems Offer

Science & Innovation tenants


Deeplabs Case Study








Higher rental rates, longer lease terms, higher renewals ratios



Strong rental premium achieved through asset transformation

Higher average rental premium captured





Creation of the leading Science & Innovation Platform in European Key Cities


Strong Science & Innovation platform with European Ambition

Strengthen existing footprint for Deeplabs' value proposal

- Initial portfolio with c.€0.4bn assets with established ecosystems in Madrid and Barcelona
- Embedded incremental returns through transformation: rental premiums, enhanced contract maturities and higher asset values

European build-up

- Additional growth opportunities leveraging on current S&I tenants
- Strong European growth ambition with a targeted pipeline of €2bn
 - Investment pipeline of €0.7bn identified in 4 European cities (Paris, Lisbon, Cambridge, Amsterdam)
 - **€0.2bn pipeline secured** or in advanced conversations
- Execution of rapid build-up strategy accelerated through the use of 3rd party capital







Executive Summary


Science & innovation - Superior Growth -

Creation of a European Leader

Growth Profile & Returns

Conclusion

Pan-European growing Platform leveraging on third-party capital




Estimated market share in Spanish Life Science Segment

Creation of the European Leading operator in Science & Innovation



Continuing to drive shareholder value



Geared IRR of +15% Stabilised Yield on Investment >10%

	Short-term	Long-term
EPRA NTA	1	11
Assets Under Management	1	111
EPRA EPS	1	111
EPRA LTV	+1%	Stable



01 Executive Summary

02 Science & innovation - Superior Growth -

Creation of a European Leader

Growth Profile & Returns

05 Conclusion



Colonial & Stoneshield to set up the Leading Platform in Science & Innovation

Strong Growth of Science & Innovation in Europe

- Science and Innovation real estate is surging, driven by shifts in demographics, Al-driven tech and geopolitics
- Europe is committing record breaking R&D budgets to fuel the innovation economy
- Established Science & Innovation ecosystems attract high quality tenants

Alpha Deeplabs: A Leading Platform as the basis for International Growth


- Dominant market position in Spain with top-tier S&I campuses in Madrid and Barcelona
- Prime ecosystems built to attract world-class talent, tenants, and global capital
- Poised to lead the European market as the first fully integrated S&I platform across geographies

Colonial's Urban Transformation enhanced through European S&I

- Investment with high double-digit returns: +15% Geared IRR
- Rapid build up strategy accelerated through third party capital
- Accretive transaction on an EPS and NTA basis
- Strategic opportunity through first mover advantage



THANK YOU



https://www.inmocolonial.com/en/shareholders-and-investors





Spain, emerging markets with strong fundamentals

Madrid



Corporate ecosystems

√ 300+ S&I established companies

R&D Investment

- ✓ €2,000m+ investment (43% public)
- ✓ €800m+ budget/year for Scientific Research

S&I Education

2nd in # of S&I students in Spain

√ 50.000+ S&I students

Infrastructure

- √ 86 hospitals
- √ 8 health research centres
- 17 universities (public and private)

Barcelona



Corporate ecosystems

5th European startup hub in tech

#34 in science output worldwide (#8 in Europe)

- √ 1,350+ S&I companies (Catalonia)
- √ 75% of all clinical trials in Spain

R&D Investment

- √ €1,025m FDI
- ✓ €130m budget for 2024-27

S&I Education

1st in # of S&I students in Spain

√ 52.000+ S&I students


Infrastructure

58 hospitals, 91 research institutions and 12 universities

Landmark investments validate Madrid & Barcelona



"AstraZeneca will invest €1.3 billion in developing an R&D center in Barcelona, reinforcing Spain as a key hub for biotechnology and pharmaceutical innovation in Europe."



"AstraZeneca will allocate €1 billion to build a production facility in Madrid, for the manufacturing of innovative medicines and securing global supply from the country."



"The Bellvitge Innovation and Health BioCluster in Barcelona will become a benchmark in biomedicine, with more than 556,000 sqm and 50,000 new jobs



"Grifols will invest €360 million in its new industrial center in Barcelona, strengthening its plasma-based therapy production capabilities




"Globant to invest €250 million in Madrid for its new artificial intelligence innovation center, reinforcing the city's role as a growing tech hub in Europe."



"Pfizer will invest €100 million in Madrid to expand its pharmaceutical manufacturing capabilities, strengthening the city's position as a key production hub in Europe."

Diversified tenant base with best in class in innovation names











































































Ecosystem with high growth tenants already in place

Growing Science & Innovation consolidated tenant base...



Technology & Quantum ALIZENT ADER XOOPLE' Robotics newline FRACTALIA ** EBVEIektronik


Energy & Environment



Aerospace & Defense



...benefits from enduring megatrends



Sources: Eurostat, Statista, CW, Moody's, McKinsey, EU Commission



A leading sponsor with contrasted experience in consolidation of RE platforms

Stoneshield is a highly reputable sponsor with a differentiated investment approach and superior sourcing capabilities leading to consistent returns

Stoneshield DNA

Seasoned investor in real estate assets and real estate related corporates, with a distinct focus in Southern Europe

- DNA Disciplined, bottom-up underwriting with emphasis on acquiring assets at a discount to market with prudent use of leverage (<50% LTV)
- VALUE CREATION Expertise in transforming assets into institutional-quality products, focusing on supply-constrained sectors
- PROVEN TRACK RECORD Opportunistic funds I and II are highly ranked in Europe, oversubscribed at their hard caps and prioritize prudent leverage
 - ✓ Fund III closing at €750 million in Q1 2024
- Stoneshield has been recognized as PERE's top 100 global ranking and #1 in Southern Europe as most successful fundraising franchise over past 5 years
- INVESTOR SUPPORT Backed by institutional investors from North America, EMEA and Asia

EXPERIENCED TEAM - Successful €10bn+ realized track record in Spain and over €3.0bn raised for discretionary funds, with €100m+ GP commitment



Differentiated Investment Approach

Thematic investing in supply-constrained and recession-resistant sectors by leveraging vertically integrated real estate platforms

- Superior sourcing capabilities in Iberia through deeply established local relationships, having underwritten >€100bn of Iberian real estate
- On-the-ground team with the ability to execute smaller ticket deals in an agile manner and aggregate them into platforms

OPPORTUNISTIC

Expert execution converting impaired assets into institutional core like product

FULL SPECTRUM OF RE CAPACITIES

First mover advantage with proofof-concept in each high-conviction target sector

PLATFORMS

Strong track record of market aggregation/consolidation through M&A in portfolio companies

Leading investor in Operational real estate

DATA CENTERS LIVING

SCIENCE &

INNOVATION

INDUSTRIAL

- Scaled a platform registering c.78% gross IRR / 2.0x equity multiple for Stoneshield's investors
- Stake owner of major homebuilder, Neinor Homes. c.€1bn market cap with c.2,500 units delivered
- Consolidated Iberian leader with a >€1bn platform STUDENT HOUSING >50 PBSA schemes and >10k beds across 20 cities
 - Pioneer in the sector taking up over 30%+ of the Spanish market through a portfolio of 22 buildings with a total value of c.€370m
 - c. €150m, committed capital and a growth path to become a €1bn platform in the next 3 years

XDATA QUARK






/deeplabs



Colonial



www.inmocolonial.com © 2025 Colonial